exposing Parkinson's disease's voices and faces.

Published Date: 26 Apr 2023

One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.

Read Full News

Latest News

Brain Chat: Neck and Neck: A Race to the Right Diagnosis Mitzi Joi Williams, MD

Williams, MD, is joined by Marcus Gates, MD, and they discuss recognizing cervical nerve root and spinal cord compression, navigating treatment options, and determining when surgery may be appropriate.

PrimeC Lowers Neuron-Derived TDP-43, Informing Phase 3 PARAGON Trial in ALS Isabella Ciccone, MPH

Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.

NeurologyLive® Brain Games: November 8, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery!

ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis Isabella Ciccone, MPH

Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.

NeurologyLive® Friday 5 — November 6, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.

This Week on NeurologyLive® — November 9, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Todays Updates

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

FDA Action Update, October 2026: Approval, Acceptance, and Designations Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

T-Cell Engager Cizutamig Shows Early Efficacy Signal in Generalized Myasthenia Gravis Marco Meglio

Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Todays Updates

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

FDA Action Update, October 2026: Approval, Acceptance, and Designations Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

T-Cell Engager Cizutamig Shows Early Efficacy Signal in Generalized Myasthenia Gravis Marco Meglio

Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Latest News

Williams, MD, is joined by Marcus Gates, MD, and they discuss recognizing cervical nerve root and spinal cord compression, navigating treatment options, and determining when surgery may be appropriate.

Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery!

Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.

Here's some of what is coming soon to NeurologyLive® this week.

News All Time

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

Distinguishing Lambert-Eaton Myasthenic Syndrome From Myasthenia Gravis: Ocular and Systemic Clues Isabella Ciccone, MPH

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

NeurologyLive® Friday 5 — October 30, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.

Understanding Advances Shaping Precision Medicine for Generalized Myasthenia Gravis Marco Meglio

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials Isabella Ciccone, MPH

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design Isabella Ciccone, MPH, M. Scott Perry, MD, Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines Louie Pasculli, Talya Fleming, MD, Sara Cuccurullo, MD

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis Louie Pasculli, Kim Henriksen, PhD

Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.

World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number Isabella Ciccone, MPH, Brian Snelling, MD

Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.

World Stroke Day: Preventing Perioperative Stroke With Predictive Tools Marco Meglio, Shadi Yaghi, MD

Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.

Recommended News For You

Are Microplastics Feeding Cancer Risk?

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

'Ray of hope': New developments in the fight against various cancers.

Obesity-related cancer rising among both younger and older adults worldwide, study finds

Year in Review: Non-Small Cell Lung Cancer

Breast cancer prevention: How nurse practitioners and physician assistants can help

Recommended Articles For You

Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring 

Pediatric Cancer Cell Metabolism During Development 

Preventing Treatment-Related Secondary Malignancies: Evidence-Based Strategies for Clinical Practice 

Clinical Analysis of Prostate Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is global cancer care losing its human touch?

2.

Pressing the Sleep button could have a positive impact on cognition.

3.

Do I qualify for a cancer clinical trial?

4.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

5.

Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.

1.

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection

2.

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed

3.

Beyond the Organs: Navigating the Era of Tissue-Agnostic Therapies in Modern Cancer Management

4.

Transformative Frameworks in Oncology for Better Care

5.

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

3.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

4.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

5.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot